Status:
UNKNOWN
The Incidence and Risk Factors of Side Effects During the Initial Phase of Rifater Therapy - a Prospective Study
Lead Sponsor:
E-DA Hospital
Conditions:
Tuberculosis
Eligibility:
All Genders
18+ years
Brief Summary
Tuberculosis remains one of the largest health problems in the world today. Multidrug therapy is necessary to cure tuberculosis patients and to prevent the selection of drug-resistant mutants, however...
Eligibility Criteria
Inclusion
- Newly diagnosed pulmonary TB and extrapulmonary TB patients
- No previous anti-TB drugs treatment
- Age more than 18years old
Exclusion
- Expected life \< 6months
- Baseline AST and ALT \> 3 fold upper limit of normal (ULN) or total bilirubin\>2mg/dl
- Age less than 18years old
Key Trial Info
Start Date :
October 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01182259
Start Date
October 1 2009
Last Update
August 16 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
E-DA hospital
Kaohsiung City, Taiwan